|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| License revenue | |||
| Operating expenses: | |||
| Research and development expenses | |||
| General and administrative expenses | |||
| Total operating expenses | |||
| Loss from operations | |||
| Other income : | |||
| Change in fair value of Series A common stock warrant liability | |||
| Interest income and other, net | |||
| Total other income | |||
| Net loss | |||
| Net unrealized gain (loss) on marketable securities | |||
| Total other comprehensive gain (loss) | |||
| Total comprehensive loss | |||
| Net loss per share, basic (in dollars per share) | |||
| Net loss per share, diluted (in dollars per share) | |||
| Weighted-average shares outstanding, basic (in shares) | |||
| Weighted-average shares outstanding, diluted (in shares) |
Loading...
